Scholar Rock (NASDAQ:SRRK) Stock Price Down 5.7% - Time to Sell?

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) shares traded down 5.7% during trading on Friday . The company traded as low as $34.99 and last traded at $34.24. 375,557 shares traded hands during trading, a decline of 67% from the average session volume of 1,137,121 shares. The stock had previously closed at $36.32.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Wednesday, June 18th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Stock Performance

The company has a quick ratio of 10.25, a current ratio of 10.25 and a debt-to-equity ratio of 0.16. The stock has a fifty day moving average price of $31.65 and a two-hundred day moving average price of $35.97. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of -13.15 and a beta of 0.28.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the previous year, the business earned ($0.59) EPS. As a group, analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Insider Activity at Scholar Rock

In related news, Director Jeffrey S. Flier sold 6,075 shares of the company's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $29.73, for a total value of $180,609.75. Following the completion of the transaction, the director now directly owns 24,070 shares in the company, valued at approximately $715,601.10. This represents a 20.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Akshay Vaishnaw sold 6,750 shares of Scholar Rock stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $200,610.00. Following the completion of the sale, the insider now owns 616,205 shares of the company's stock, valued at $18,313,612.60. This trade represents a 1.08% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,000 shares of company stock valued at $966,651. Company insiders own 13.30% of the company's stock.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently bought and sold shares of SRRK. FMR LLC grew its stake in shares of Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after buying an additional 3,439,215 shares during the period. Marshall Wace LLP grew its position in Scholar Rock by 1,283.7% during the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after acquiring an additional 2,732,546 shares during the period. Norges Bank acquired a new stake in Scholar Rock during the fourth quarter worth about $86,043,000. Fairmount Funds Management LLC purchased a new position in shares of Scholar Rock in the 4th quarter worth about $84,839,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Scholar Rock in the 4th quarter worth about $68,930,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.